Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Andrea Gori and Massimo Puoti.
Andrea Gori
Connection Strength
0.466
Massimo Puoti
  1. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017; 12(2):e0172159.
    View in: PubMed
    Score: 0.177
  2. SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. BMC Infect Dis. 2021 Feb 17; 21(1):184.
    View in: PubMed
    Score: 0.058
  3. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018 12; 38(12):2190-2198.
    View in: PubMed
    Score: 0.049
  4. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
    View in: PubMed
    Score: 0.047
  5. Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. Eur J Clin Microbiol Infect Dis. 2018 May; 37(5):871-881.
    View in: PubMed
    Score: 0.047
  6. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
    View in: PubMed
    Score: 0.045
  7. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clin Infect Dis. 2017 03 01; 64(5):680-683.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.